Last reviewed · How we verify
extended release of octreotide
At a glance
| Generic name | extended release of octreotide |
|---|---|
| Also known as | LF-PB 30 mg |
| Sponsor | Chemi S.p.A. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (PHASE3)
- Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy (PHASE2)
- Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly (PHASE3)
- Extended-release of Octreotide (LF-PB) for the Treatment of Seroma (PHASE2)
- Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea (PHASE2)
- Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- extended release of octreotide CI brief — competitive landscape report
- extended release of octreotide updates RSS · CI watch RSS
- Chemi S.p.A. portfolio CI